Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
作者
Frederick J. Raal,Jean Bergeron,Daniel Gaudet,Robert S. Rosenson,David Sullivan,Traci Turner,Robert A. Hegele,Christie M. Ballantyne,Joshua W. Knowles,Nicholas J. Leeper,Ira J. Goldberg,Rong Zhou,Ma’an Muhsin,Jennifer Hellawell,James Hamilton,Gerald F. Watts